JP2021523712A5 - - Google Patents

Info

Publication number
JP2021523712A5
JP2021523712A5 JP2020563659A JP2020563659A JP2021523712A5 JP 2021523712 A5 JP2021523712 A5 JP 2021523712A5 JP 2020563659 A JP2020563659 A JP 2020563659A JP 2020563659 A JP2020563659 A JP 2020563659A JP 2021523712 A5 JP2021523712 A5 JP 2021523712A5
Authority
JP
Japan
Prior art keywords
nucleic acid
acid sequences
cmv
rmva
cmv antigen
Prior art date
Application number
JP2020563659A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021523712A (ja
JPWO2019217922A5 (https=
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/031866 external-priority patent/WO2019217922A1/en
Publication of JP2021523712A publication Critical patent/JP2021523712A/ja
Publication of JPWO2019217922A5 publication Critical patent/JPWO2019217922A5/ja
Publication of JP2021523712A5 publication Critical patent/JP2021523712A5/ja
Pending legal-status Critical Current

Links

JP2020563659A 2018-05-11 2019-05-10 安定性が改善された遺伝子組み換え組換えワクシニアアンカラ(rmva)ワクチン及びその調製方法 Pending JP2021523712A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862670656P 2018-05-11 2018-05-11
US62/670,656 2018-05-11
PCT/US2019/031866 WO2019217922A1 (en) 2018-05-11 2019-05-10 Genetically modified recombinant vaccinia ankara (rmva) vaccines of improved stability and methods of preparation thereof

Publications (3)

Publication Number Publication Date
JP2021523712A JP2021523712A (ja) 2021-09-09
JPWO2019217922A5 JPWO2019217922A5 (https=) 2022-05-18
JP2021523712A5 true JP2021523712A5 (https=) 2022-05-18

Family

ID=68467105

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020563659A Pending JP2021523712A (ja) 2018-05-11 2019-05-10 安定性が改善された遺伝子組み換え組換えワクシニアアンカラ(rmva)ワクチン及びその調製方法

Country Status (5)

Country Link
US (1) US12054736B2 (https=)
EP (1) EP3790578A4 (https=)
JP (1) JP2021523712A (https=)
CN (1) CN112512568A (https=)
WO (1) WO2019217922A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8580276B2 (en) 2009-06-05 2013-11-12 City Of Hope Genetically stable recombinant modified vaccinia ankara (rMVA) vaccines and methods of preparation thereof
EP3529353A4 (en) 2016-10-19 2020-05-13 City of Hope USE OF TRIPLEX-CMV VACCINE IN CAR-T-CELL THERAPY
KR20250005247A (ko) 2022-04-13 2025-01-09 시티 오브 호프 Cmv-hiv 특이적 키메라 항원 수용체 t 세포
WO2025184598A1 (en) * 2024-03-01 2025-09-04 City Of Hope Stable and immunogenic cmv vaccine

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6835383B2 (en) 2000-03-23 2004-12-28 City Of Hope Protein kinase deficient, immunologically active CMVpp65 mutants
CN102703393A (zh) 2002-05-16 2012-10-03 巴法里安诺迪克有限公司 表达插入痘病毒基因组中的同源基因的重组痘病毒
US7501127B2 (en) * 2002-05-16 2009-03-10 Bavarian Nordic A/S Intergenic regions as novel sites for insertion of HIV DNA sequences in the genome of Modified Vaccinia virus Ankara
US7163685B2 (en) 2003-04-16 2007-01-16 City Of Hope Human cytomegalovirus antigens expressed in MVA and methods of use
US8580276B2 (en) * 2009-06-05 2013-11-12 City Of Hope Genetically stable recombinant modified vaccinia ankara (rMVA) vaccines and methods of preparation thereof
US8326547B2 (en) * 2009-10-07 2012-12-04 Nanjingjinsirui Science & Technology Biology Corp. Method of sequence optimization for improved recombinant protein expression using a particle swarm optimization algorithm
WO2011047324A1 (en) 2009-10-16 2011-04-21 The U.S.A. As Represented By The Secretary , Department Of Health And Human Services . Recombinant modified vaccinia ankara (mva) vaccinia virus containing restructured insertion sites
JP2013544504A (ja) 2010-10-11 2013-12-19 ノバルティス アーゲー 抗原送達プラットフォーム
DK2877580T3 (en) 2012-07-27 2019-04-23 Hope City VAT VACCINE TO DELIVER A UL128 COMPLEX AND PREVENT CMV INFECTION
WO2018075813A1 (en) * 2016-10-19 2018-04-26 City Of Hope Use of endogenous viral vaccine in chimeric antigen receptor t cell therapy

Similar Documents

Publication Publication Date Title
JP2021523712A5 (https=)
Fisher et al. Recombinant adenovirus deleted of all viral genes for gene therapy of cystic fibrosis
JP7118062B2 (ja) リサウイルス抗原を有するチンパンジーアデノウイルス構築物
JP2020511940A5 (https=)
JP2007135598A (ja) ポリエピトープワクチン
JP7092663B2 (ja) 組換えオルフウイルスベクター
CN111108192A (zh) 非人类人猿腺病毒核酸序列和氨基酸序列、含有其的载体及其用途
WO2021224946A1 (en) Coronavirus vaccine through nasal immunization
JP7818587B2 (ja) 組換えhvt及びその使用
US12054736B2 (en) Genetically modified recombinant vaccinia ankara (RMVA) vaccines of improved stability and methods of preparation thereof
JP2018521651A5 (https=)
JP2023512294A (ja) 天然dnaまたは合成dnaによって作製されたポックスウイルスベースのベクターおよびその使用法
CN118308379A (zh) 爱泼斯坦-巴尔病毒抗原构建体
KR0181976B1 (ko) 미생물의 세포, 조직 또는 숙주 지향성을 변화시키는 방법, 이 방법으로 수득된 재조합 미생물, 및 의학 및 수의학 분야에서 이들을 사용하는 방법
WO2015024484A1 (zh) 一种新型狂犬病疫苗及其制备方法
TWI901715B (zh) 大猩猩腺病毒核酸及胺基酸序列,包含彼之載體,及其用途
WO1992001045A1 (en) Equine herpesvirus-4 tk- vaccine
JP6235697B2 (ja) 変異ワクシニアウイルス株、その使用およびそれを作製する方法
JPWO2019217922A5 (https=)
Marsland et al. Construction of a recombinant orf virus that expresses an Echinococcus granulosus vaccine antigen from a novel genomic insertion site
Strive et al. Development of canine herpesvirus based antifertility vaccines for foxes using bacterial artificial chromosomes
Yll-Pico et al. Highly stable and immunogenic CMV T cell vaccine candidate developed using a synthetic MVA platform
JPS615786A (ja) 単純ヘルペスウイルス遺伝子を組込んだ組換えdna、形質転換動物細胞および単純ヘルペスウイルス蛋白質の製法
JPH07503843A (ja) マレック病ウイルス組換えポックスウイルスワクチン
JPH03504196A (ja) 新規組換えワクチニアウイルス発現ベクター及びその選択方法